# Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery

> **NCT01206140** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (actual)

## Conditions studied

- Recurrent Adult Soft Tissue Sarcoma
- Stage III Adult Soft Tissue Sarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Selumetinib
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01206140
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01206140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01206140, "Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01206140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*